Cargando…

Randomized trial of DRV/r or LPV/r QD monotherapy vs maintaining a PI/r-based antiretroviral regimen in persons with suppressed HIV replication

INTRODUCTION: PI/r monotherapy has been suggested as an attainable maintenance strategy in patients achieving stable HIV suppression in plasma. The objective of trial was to compare the virological outcome of two different PI/r QD monotherapy strategies (LPV/r or DRV/r) with maintaining a triple PI/...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pinnetti, Carmela, Lorenzini, Patrizia, Cozzi-Lepri, Alessandro, Sandrine, Ottou, Tommasi, Chiara, Zaccarelli, Mauro, Federico Perno, Carlo, Rosaria Capobianchi, Maria, Girardi, Enrico, Antinori, Andrea, Ammassari, Adriana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Poster Sessions – Abstract P277
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225440/ https://www.ncbi.nlm.nih.gov/pubmed/25397553 http://dx.doi.org/10.7448/IAS.17.4.19809

Ejemplares similares

No significant association between patient self-reported non-adherence to antiretrovirals and HIV-tropism: a preliminary analysis
por: Ammassari, A, et al.
Publicado: (2012)

Potential implications of CYP3A4, CYP3A5 and MDR-1 genetic variants on the efficacy of Lopinavir/Ritonavir (LPV/r) monotherapy in HIV-1 patients
por: Berno, Giulia, et al.
Publicado: (2014)

Effectiveness and durability of darunavir/ritonavir (DRV/r) in DRV/r-experienced HIV-1-infected patients in routine clinical practice
por: Antinori, Andrea, et al.
Publicado: (2014)

CSF LPV concentrations and viral load in viral suppressed patients on LPV/r monotherapy given once daily
por: Tiraboschi, Juan, et al.
Publicado: (2014)

An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy
por: Cozzi-Lepri, Alessandro, et al.
Publicado: (2014)

Safety of darunavir/ritonavir (DRV/r) in HIV-1-infected DRV/r-experienced and -naïve patients: analysis of data in the real-world setting in Italy
por: Antinori, Andrea, et al.
Publicado: (2014)

Apport de la technique de double diffusion DLCO-DLNO dans l’évaluation des séquelles fonctionnelles respiratoires post-COVID
por: Sesé, L., et al.
Publicado: (2022)

Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort
por: Pinnetti, Carmela, et al.
Publicado: (2014)

Outcomes related to 4864 pregnancies with exposure to lopinavir/ritonavir (LPV/r)
por: Tookey, Pat, et al.
Publicado: (2014)

DRV concentrations and viral load in CSF in patients on DRV/r 600/100 or 800/100mg once daily plus two NRTI
por: Di Yacovo, Silvana, et al.
Publicado: (2014)

ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naïve HIV-1-infected adults
por: Orkin, C, et al.
Publicado: (2010)

Central nervous system penetration-effectiveness rank does not reliably predict neurocognitive impairment in HIV-infected individuals
por: Libertone, Raffaella, et al.
Publicado: (2014)

Acute HIV infection (AHI) in a specialized clinical setting: case-finding, description of virological, epidemiological and clinical characteristics
por: Ammassari, Adriana, et al.
Publicado: (2014)

Relationship between body mass index and bone mineral density in HIV-infected patients referred for DXA
por: Pinnetti, Carmela, et al.
Publicado: (2014)

Analysis of BENCHMRK 1 & 2 using PhenoSense® assay for darunavir (DRV/r) resistance and exploration of functional monotherapy with RAL vs DRV
por: Rockstroh, J, et al.
Publicado: (2010)

Low-level viraemia during treatment with darunavir/r monotherapy versus DRV/r + 2NRTIs in the MONET trial
por: Clumeck, N, et al.
Publicado: (2010)

Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis
por: Zaccarelli, Mauro, et al.
Publicado: (2014)

Less frequent follow-up in routine care than in trials does not impact resistance selection in patients failing DRV/r or ATV/r first line treatment
por: Marcelin, Anne-Genevieve, et al.
Publicado: (2014)

APRI and FIB-4 scores are not associated with neurocognitive impairment in HIV-infected persons
por: Libertone, Raffaella, et al.
Publicado: (2014)

INFECÇÃO POR ADENOVÍRUS (ADE), INFLUENZA A (FLUA), INFLUENZA B (FLUB), PARAINFLUENZA 1, 2 E 3 E VÍRUS RESPIRATÓRIO SINCICIAL (VRS) EM CRIANÇAS < 5 ANOS HOSPITALIZADAS: ANTES E DURANTE A PANDEMIA DE COVID-19
por: Cavatão, Fernando Guimarães, et al.
Publicado: (2022)

Diabète et Covid-19 : quelle relation?
por: Ben Soltane, H., et al.
Publicado: (2023)

Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study
por: Deng, Lisi, et al.
Publicado: (2020)

Evolution of Framingham cardiovascular risk score in HIV-infected patients initiating EFV- and LPV/r-based HAART in a Latin American cohort
por: Cecchini, Diego, et al.
Publicado: (2014)

Cost/efficacy analysis of preferred Spanish AIDS study group regimens and the dual therapy with LPV/r+3TC for initial ART in HIV infected adults
por: Gatell, Josép M, et al.
Publicado: (2014)

Analysis of major and minor IAS-USA PI mutations in the MONET trial of darunavir/ritonavir monotherapy versus DRV/r + 2NRTIs
por: Pulido, F, et al.
Publicado: (2010)

144-week outcomes of lopinavir/ritonavir (LPV/r)-based first-line ART in 1,409 HIV-infected patients: data from the German STAR/STELLA cohort
por: Wolf, Eva, et al.
Publicado: (2014)

HIV Lipodystrophy in Participants Randomised to Lopinavir/Ritonavir (LPV/r) +2–3 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) or LPV/r + Raltegravir as Second-Line Antiretroviral Therapy
por: Martin, Allison, et al.
Publicado: (2013)

Reactivation of occult HBV infection in an HIV/HCV Co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature
por: Fabbri, Gabriele, et al.
Publicado: (2017)

Adherence in HIV-positive patients treated with single-tablet regimens and multi-pill regimens: findings from the COMPACT study
por: Antinori, A, et al.
Publicado: (2012)

Europeanization, European integration and financial services : developing theoretical frameworks and synthesising methodological approaches /
por: Howell, Kerry E.
Publicado: (2004)

Report on the state of the European Union /
Publicado: (2005)

Estructura económica de la Unión Europea /
por: Berumen Arellano, Sergio
Publicado: (2006)

La quiebra de Europa : una crisis cultural /
por: Martínez de Murguía, Beatriz, 1962-
Publicado: (2017)

Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy
por: Cozzi-Lepri, Alessandro, et al.
Publicado: (2014)

Pharmacokinetic (PK) and pharmacodynamic analyses of once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial
por: Sekar, V, et al.
Publicado: (2010)

Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort
por: d’Arminio Monforte, Antonella, et al.
Publicado: (2016)

Increased incidence of sexually transmitted diseases in the recent years: data from the ICONA cohort
por: Cingolani, Antonella, et al.
Publicado: (2014)

The dual-target approach in viral HIV-1 viremia testing: An added value to virological monitoring?
por: Amendola, Alessandra, et al.
Publicado: (2020)

Correction: The dual-target approach in viral HIV-1 viremia testing: An added value to virological monitoring?
por: Amendola, Alessandra, et al.
Publicado: (2020)

Simplification to Stribild vs continuation of RTV-boosted DRV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-PI subgroup analysis
por: Arribas, Jose, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ij0f8iciintc0qljlb46bqrmp1